Your browser doesn't support javascript.
loading
PD-1 inhibitor combined with Docetaxel exerts synergistic anti-prostate cancer effect in mice by down-regulating the expression of PI3K/AKT/NFKB-P65/PD-L1 signaling pathway.
Zhou, Sixu; Wang, Baogui; Wei, Yingying; Dai, Peiru; Chen, Yan; Xiao, Yingyi; Xia, Hongmei; Chen, Chunlin; Yin, Weihua.
Afiliación
  • Zhou S; College of Chemistry and Biological Engineering, Yichun University, Yichun, Jiangxi, China.
  • Wang B; College of Chemistry and Biological Engineering, Yichun University, Yichun, Jiangxi, China.
  • Wei Y; College of Chemistry and Biological Engineering, Yichun University, Yichun, Jiangxi, China.
  • Dai P; College of Chemistry and Biological Engineering, Yichun University, Yichun, Jiangxi, China.
  • Chen Y; College of Chemistry and Biological Engineering, Yichun University, Yichun, Jiangxi, China.
  • Xiao Y; College of Chemistry and Biological Engineering, Yichun University, Yichun, Jiangxi, China.
  • Xia H; The People's Hospital of Yichun Affiliated to Clinical Medicine School of Yichun University in Jiangxi Province, Yichun, Jiangxi, China.
  • Chen C; College of Chemistry and Biological Engineering, Yichun University, Yichun, Jiangxi, China.
  • Yin W; The People's Hospital of Yichun Affiliated to Clinical Medicine School of Yichun University in Jiangxi Province, Yichun, Jiangxi, China.
Cancer Biomark ; 40(1): 47-59, 2024.
Article en En | MEDLINE | ID: mdl-38306024
ABSTRACT

BACKGROUND:

Docetaxel is a yew compound antitumor agent with accurate antitumor efficacy, but its application is limited due to the high and serious adverse effects, and finding effective combination therapy options is a viable strategy. Immune checkpoint inhibitors have become hotspots in enhancing anti-tumor immunity by blocking immune checkpoint signaling pathways, but their response rate to monotherapy use is not high and the efficacy is minimal.

OBJECTIVE:

To explore the anti-tumor effects and mechanisms of the combination of PD-1 inhibitors and Docetaxel through in vivo experiments and develop a feasible combination treatment for the therapy of prostate cancer.

METHODS:

Tumor-bearing mice were subcutaneously injected with 0.1 ml RM-1 cells. Treatment were taken when the tumor growed up to 3 mm, after which the tumor and spleen were removed to test the antitumor effect with Flow cytometric (FACS) analysis, Immunohistochemistry, Western Blot.

RESULTS:

In this experiment, we found that PD-1 inhibitors combined with Docetaxel had a synergistic effect on mouse prostate cancer, inhibited the growth of prostate cancer, improved survival and reduced adverse reactions, increased spleen and tumor infiltrative CD4+ and CD8+ T cells, especially in group combination with low-dose Docetaxel, and were related to the PI3K/AKT/NFKB-P65/PD-L1 signaling pathway.

CONCLUSION:

Our study confirms that PD-1 inhibitors in combination with Docetaxel are a viable combination strategy and provide a safe and effective combination option for the clinical treatment of prostate cancer.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Transducción de Señal / Fosfatidilinositol 3-Quinasas / Proteínas Proto-Oncogénicas c-akt / Antígeno B7-H1 / Receptor de Muerte Celular Programada 1 / Docetaxel Límite: Animals Idioma: En Revista: Cancer Biomark Asunto de la revista: BIOQUIMICA / NEOPLASIAS Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Transducción de Señal / Fosfatidilinositol 3-Quinasas / Proteínas Proto-Oncogénicas c-akt / Antígeno B7-H1 / Receptor de Muerte Celular Programada 1 / Docetaxel Límite: Animals Idioma: En Revista: Cancer Biomark Asunto de la revista: BIOQUIMICA / NEOPLASIAS Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Países Bajos